Literature DB >> 21811923

Effects of borneol on the intestinal transport and absorption of two P-glycoprotein substrates in rats.

Huijuan He1, Qi Shen, Jian Li.   

Abstract

As the most prevalent route of delivery, oral administration has the challenge of potentially low bioavailability in part because P-glycoprotein (P-gp) in the intestinal tract affects absorption. Therefore, absorption enhancers or P-gp inhibitors are strategies to solve this problem. The aim of the present study was to investigate the effects of borneol on transportation of colchicine and rhodamine123, two P-gp substrates, in rats. In vitro transportation was assessed with a diffusion chamber system with isolated rat intestines. Different concentrations of borneol (10, 40 and 80 μg/mL) were prepared in solutions with two P-gp substrates compared with blank solutions. The in vivo effects on colchicine were assessed by a pharmacokinetic study. Borneol enhanced the absorptive transport of two P-gp substrates, which was relevant to the concentration. A pharmacokinetic study showed that in the presence of borneol, a significant increase in C(max) and AUC(0→8) of colchicine occurred when compared to colchicine alone. The study showed that borneol affected two P-gp substrates in the intestine, possibly by inhibiting the effects of P-gp and enhancing intestinal absorption of drugs. Therefore, borneol could be developed as a P-gp inhibitor and absorptive enhancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21811923     DOI: 10.1007/s12272-011-0714-y

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  8 in total

1.  Effect of natural borneol on the pharmacokinetics and distribution of nimodipine in mice.

Authors:  Chun Wu; Qiongfeng Liao; Meicun Yao; Xinjun Xu; Yuting Zhou; Xueying Hou; Zhiyong Xie
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-05-15       Impact factor: 2.441

Review 2.  Borneol: a Promising Monoterpenoid in Enhancing Drug Delivery Across Various Physiological Barriers.

Authors:  Madhur Kulkarni; Niserga Sawant; Anjali Kolapkar; Aishwarya Huprikar; Namita Desai
Journal:  AAPS PharmSciTech       Date:  2021-04-28       Impact factor: 3.246

3.  The use of borneol as an enhancer for targeting aprotinin-conjugated PEG-PLGA nanoparticles to the brain.

Authors:  Lin Zhang; Limei Han; Jing Qin; Weiyue Lu; Jianxin Wang
Journal:  Pharm Res       Date:  2013-04-25       Impact factor: 4.200

4.  Enhancing both oral bioavailability and brain penetration of puerarin using borneol in combination with preparation technologies.

Authors:  Tao Yi; Dandan Tang; Fan Wang; Jiqiong Zhang; Jiao Zhang; Jirui Wang; Xiaoyu Xu; Jifen Zhang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

5.  Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles.

Authors:  Liang Zou; Di Wang; Yichen Hu; Chaomei Fu; Wei Li; Liping Dai; Lin Yang; Jinming Zhang
Journal:  Oncotarget       Date:  2017-07-31

Review 6.  Recent Progress on the Synergistic Antitumor Effect of a Borneol-Modified Nanocarrier Drug Delivery System.

Authors:  Jinxiu Li; Qian Xie; Rong Ma; Yong Li; Jianmei Yuan; Mihong Ren; Hongyan Li; Jiajun Wang; Danni Lu; Zhuo Xu; Jian Wang
Journal:  Front Med (Lausanne)       Date:  2021-11-25

7.  Pharmacokinetic studies of multi-bioactive components in rat plasma after oral administration of Xintiantai Ⅰ extract and effects of guide drug borneol on pharmacokinetics.

Authors:  Shao-Yu Liang; Yong-Chang Zeng; Qian-Qian Jiang; Jun-Hong Wu; Zheng-Zhi Wu
Journal:  Chin Herb Med       Date:  2019-12-10

8.  Folate and Borneol Modified Bifunctional Nanoparticles for Enhanced Oral Absorption.

Authors:  Yifan Yang; Yunzhi Yin; Jun Zhang; Tiantian Zuo; Xiao Liang; Jing Li; Qi Shen
Journal:  Pharmaceutics       Date:  2018-09-04       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.